Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (2)

Search Parameters:
Authors = L. Nicolas Gonzalez Castro ORCID = 0000-0001-7699-5188

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
14 pages, 668 KiB  
Review
Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes
by Daniel Chiu, John Rhee and L. Nicolas Gonzalez Castro
Antibodies 2023, 12(3), 50; https://doi.org/10.3390/antib12030050 - 31 Jul 2023
Cited by 10 | Viewed by 9069
Abstract
Paraneoplastic antibody syndromes result from the anti-tumor antibody response against normal antigens ectopically expressed by tumor cells. Although this antibody response plays an important role in helping clear a nascent or established tumor, the engagement of antigens expressed in healthy tissues can lead [...] Read more.
Paraneoplastic antibody syndromes result from the anti-tumor antibody response against normal antigens ectopically expressed by tumor cells. Although this antibody response plays an important role in helping clear a nascent or established tumor, the engagement of antigens expressed in healthy tissues can lead to complex clinical syndromes with challenging diagnosis and management. The majority of known paraneoplastic antibody syndromes have been found to affect the central and peripheral nervous system. The present review provides an update on the pathophysiology of paraneoplastic neurologic syndromes, as well as recommendations for their diagnosis and treatment. Full article
Show Figures

Figure 1

21 pages, 776 KiB  
Review
The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors
by Paolo Alimonti and L. Nicolas Gonzalez Castro
Antibodies 2023, 12(2), 27; https://doi.org/10.3390/antib12020027 - 4 Apr 2023
Cited by 6 | Viewed by 3928
Abstract
Antibodies against immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple aggressive malignancies, including melanoma and non-small cell lung cancer. ICIs for the treatment of primary and metastatic brain tumors have been used with varying degrees of success. Here, we discuss the [...] Read more.
Antibodies against immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple aggressive malignancies, including melanoma and non-small cell lung cancer. ICIs for the treatment of primary and metastatic brain tumors have been used with varying degrees of success. Here, we discuss the available evidence for the use of ICIs in the treatment of primary and metastatic brain tumors, highlighting challenges and opportunities for furthering this type of cancer immunotherapy in neuro-oncology. Full article
(This article belongs to the Section Antibody-Based Therapeutics)
Show Figures

Figure 1

Back to TopTop